CC
Commodore Capital Portfolio holdings
AUM
$1.42B
1-Year Return
73.3%
This Quarter Return
+37.69%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$251M
AUM Growth
+$67.1M
(+36%)
Cap. Flow
+$40.3M
Cap. Flow
% of AUM
16.05%
Top 10 Holdings %
Top 10 Hldgs %
55.61%
Holding
35
New
7
Increased
11
Reduced
7
Closed
4
Top Buys
| 1 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$14.4M |
| 2 |
Kura Oncology
KURA
|
$11M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.8M |
| 4 |
Dyne Therapeutics
DYN
|
$6.68M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$5.51M |
Top Sells
| 1 |
Aclaris Therapeutics
ACRS
|
$7.77M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$6.43M |
| 3 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$4.32M |
| 4 |
Immunovant
IMVT
|
$3.87M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$2.97M |
Sector Composition
| 1 | Healthcare | 95.54% |
| 2 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IVA
26
Inventiva
IVA
$779M
| $3.86M | 1.54% |
262,658
+31,658
| +14% | +$465K |
|
27
Viridian Therapeutics
VRDN
$1.52B
| $3.1M | 1.24% |
+185,781
| New | +$3.1M |
|
28
Seres Therapeutics
MCRB
$165M
| $2.91M | 1.16% |
+7,065
| New | +$2.91M |
|
|
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $2.64M | 1.05% |
250,000
| – | – |
|
30
MacroGenics
MGNX
$123M
| $1.49M | 0.59% |
+46,630
| New | +$1.49M |
|
|
SNCE
31
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $1.01M | 0.4% |
5,000
| – | – |
|
32
Cyclacel Pharmaceuticals
CYCC
$16.7M
| – | – |
-74
| Closed | -$2.07M |
|
|
33
Immunovant
IMVT
$2.81B
| – | – |
-83,782
| Closed | -$3.87M |
|
34
Tempest Therapeutics
TPST
$44.5M
| – | – |
-4,744
| Closed | -$1.98M |
|
|
SURF
35
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – |
-467,796
| Closed | -$4.32M |
|